Citadel Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-113,555
| Closed | -$1.49M | – | 12947 |
|
|
2025
Q4 | $1.49M | Sell |
113,555
-735,427
| -87% | -$8.78M | ﹤0.01% | 6530 |
|
|
2025
Q3 | $6.18M | Sell |
848,982
-326,115
| -28% | -$2.21M | ﹤0.01% | 3975 |
|
|
2025
Q2 | $6.3M | Sell |
1,175,097
-195,526
| -14% | -$948K | ﹤0.01% | 3728 |
|
|
2025
Q1 | $7.32M | Buy |
1,370,623
+438,644
| +47% | +$3.07M | ﹤0.01% | 3305 |
|
|
2024
Q4 | $8.33M | Buy |
931,979
+141,225
| +18% | +$1.5M | ﹤0.01% | 3211 |
|
|
2024
Q3 | $8.71M | Sell |
790,754
-623,587
| -44% | -$6.93M | ﹤0.01% | 3132 |
|
|
2024
Q2 | $12.9M | Buy |
1,414,341
+536,190
| +61% | +$5.23M | ﹤0.01% | 2473 |
|
|
2024
Q1 | $12.4M | Buy |
878,151
+734,493
| +511% | +$9.15M | ﹤0.01% | 2651 |
|
|
2023
Q4 | $1.1M | Buy |
143,658
+122,209
| +570% | +$676K | ﹤0.01% | 6477 |
|
|
2023
Q3 | $160K | Buy |
21,449
+21,014
| +4,831% | +$179K | ﹤0.01% | 10251 |
|
|
2023
Q2 | $3.62K | Sell |
435
-18,349
| -98% | -$212K | ﹤0.01% | 13674 |
|
|
2023
Q1 | $250K | Sell |
18,784
-120,562
| -87% | -$1.63M | ﹤0.01% | 9769 |
|
|
2022
Q4 | $2.07M | Buy |
139,346
+16,870
| +14% | +$174K | ﹤0.01% | 5414 |
|
|
2022
Q3 | $1.11M | Sell |
122,476
-97,486
| -44% | -$653K | ﹤0.01% | 6779 |
|
|
2022
Q2 | $659K | Sell |
219,962
-23,827
| -10% | -$107K | ﹤0.01% | 8024 |
|
|
2022
Q1 | $1.64M | Buy |
243,789
+21,392
| +10% | +$127K | ﹤0.01% | 6535 |
|
|
2021
Q4 | $1.2M | Sell |
222,397
-88,192
| -28% | -$580K | ﹤0.01% | 7501 |
|
|
2021
Q3 | $2.75M | Sell |
310,589
-15,752
| -5% | -$151K | ﹤0.01% | 5572 |
|
|
2021
Q2 | $4.13M | Buy |
326,341
+319,219
| +4,482% | +$4.14M | ﹤0.01% | 4853 |
|
|
2021
Q1 | $124K | Sell |
7,122
-3,725
| -34% | -$67.3K | ﹤0.01% | 12259 |
|
|
2020
Q4 | $139K | Buy |
+10,847
| New | +$193K | ﹤0.01% | 9996 |
|
|
2020
Q3 | – | Sell |
-2,860
| Closed | -$113K | – | 10047 |
|
|
2020
Q2 | $111K | Buy |
+2,860
| New | +$102K | ﹤0.01% | 8935 |
|
|
2020
Q1 | – | Sell |
-1,698
| Closed | -$60K | – | 9560 |
|
|
2019
Q4 | $60K | Buy |
+1,698
| New | +$53.5K | ﹤0.01% | 8704 |
|
|
2018
Q3 | – | Sell |
-664
| Closed | -$38K | – | 9184 |
|
|
2018
Q2 | $38K | Buy |
+664
| New | +$61.2K | ﹤0.01% | 8494 |
|
|
2017
Q2 | – | Sell |
-466
| Closed | -$45K | – | 7453 |
|
|
2017
Q1 | $45K | Buy |
+466
| New | +$64.2K | ﹤0.01% | 7064 |
|
Citadel Advisors's ATXS Position: Q1 2026 in Review
Citadel Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 113,555 shares — an estimated $1.49M sold.
Citadel Advisors first reported a position in ATXS in Q1 2017 and held it in 25 quarters. The position peaked at $12.9M in Q2 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Citadel Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 113,555 Astria Therapeutics shares in Q1 2026, an estimated $1.49M.
- Citadel Advisors first reported a position in Astria Therapeutics in Q1 2017 and held it in 25 quarters.
- Citadel Advisors's Astria Therapeutics position peaked at $12.9M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.